Although most CRC tumors (80%) are thought to be initiated through dysregulation of the WNT pathway, CRC tumors with activated KRAS/BRAF/MEK/ERK appear to be associated with poor outcomes7,8 and are difficult to treat. The gene discussed is KRAS; the disease is colorectal carcinoma.